Drug intelligence / Profile preview

recombinant interleukin-20

Development stage
Preclinical
Modality
Cytokines & Interferons → Recombinant Proteins and Enzymes
01

Overview

Recombinant interleukin-20 (rIL-20) is a synthetic form of the IL-20 cytokine, a member of the IL-10 family. It acts as an agonist that signals through two distinct heterodimeric receptor complexes: the Type I receptor (composed of IL-20RA and IL-20RB) and the Type II receptor (composed of IL-22RA1 and IL-20RB). IL-20 is primarily involved in regulating epithelial cell functions, including proliferation, differentiation, and tissue repair, particularly in the skin and respiratory tract. While it plays a physiological role in wound healing, its dysregulation is implicated in inflammatory pathologies such as psoriasis and chronic obstructive pulmonary disease (COPD). In research settings, recombinant IL-20 is used to study its effects on epithelial barrier integrity and its potential as a biomarker or therapeutic target in chronic inflammatory diseases.

Other names
recombinant IL-20rIL-20rIL20rIL 20rhIL-20rhIL20rhIL 20
02

Targets

Interleukin-20 receptor type II heterodimerIL20RA (Interleukin-20 receptor subunit alpha)IL20RB (Interleukin-20 receptor subunit beta)IL22RA1 (Interleukin-22 receptor subunit alpha-1)

Beyond the preview

Go deeper on recombinant interleukin-20.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant interleukin-20.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call